Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica

Furst, 2012, Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011, Ann Rheum Dis, 71, i2, 10.1136/annrheumdis-2011-201036 Singh, 2009, Biologics for rheumatoid arthritis: An overview of Cochrane reviews, Cochrane Database Syst Rev, CD007848 Singh, 2011, Adverse effects of biologics: A network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, CD008794 Listing, 2006, Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register, Arthritis Res Ther, 8, R66, 10.1186/ar1933 Baraliakos, 2012, Biologic therapies for spondyloarthritis: What is new?, Curr Rheumatol Rep, 14, 422, 10.1007/s11926-012-0282-2 Brocq, 2009, Effect of discontinuing TNFalpha agonist therapy in patients with remission of rheumatoid arthritis, Joint Bone Spine, 76, 350, 10.1016/j.jbspin.2008.11.009 Baraliakos, 2005, Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab, Arthritis Res Ther, 7, R439, 10.1186/ar1693 Lee, 2010, Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: a retrospective analysis, Clin Rheumatol, 29, 1149, 10.1007/s10067-010-1542-z Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 964, 10.1136/ard.2009.126532 Den Broeder, 2011, Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA, Rheumatology, 49, 1801, 10.1093/rheumatology/keq060 Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107 De Punder, 2012, The prevalence of clinical remission in RA patients treated with anti-TNF: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry, Rheumatology, 51, 1610, 10.1093/rheumatology/kes078 Van den Broek, 2011, Discontinuation and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of BeSt study, Ann Rheum Dis, 70, 1389, 10.1136/ard.2010.147751 Van der Kooij, 2009, Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis, Ann Rheum Dis, 68, 914, 10.1136/ard.2008.092254 Tanaka, 2010, Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study, Ann Rheum Dis, 69, 1286, 10.1136/ard.2009.121491 Saleem, 2010, Patients with RA in remission on TNF blockers: When and whom can TNF blocker therapy be stopped?, Ann Rheum Dis, 69, 1636, 10.1136/ard.2009.117341 Gibson, 2012, Reduced dose and frecuency of Anti-TNF therapy in rheumatic diseases [EULAR 2012. Abstract OP0148], Ann Rheum Dis, 71, 103, 10.1136/annrheumdis-2012-eular.1831 Botsios, 2007, Effects of low dose etanercept in mantaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis [EULAR 2012. Abstract OP0012], Ann Rheum Dis, 66, 54 Compán-Navarro, 2011, Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease, Clin Rheumatol, 30, 993, 10.1007/s10067-011-1722-5 Lee, 2008, Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients, Clin Rheumatol, 27, 179, 10.1007/s10067-007-0674-2 López-Vives, 2012, Dose reduction and/or withdrawal of anti-TNF treatment in psoriatic arthritis [EULAR 2012 Abstract OP0161], Ann Rheum Dis, 71, 133 Cantini, 2012, Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study, Biologics, 6, 201 Tornero-Molina, 2010, Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide, Reumatol Clin, 6, 23, 10.1016/j.reuma.2009.10.006 Férnandez, 2011, Documento SER de consenso sobre el uso de teapia biológicas en artritis psoriásica, Reumatol Clin, 7, 179, 10.1016/j.reuma.2011.02.001 Juanola, 2011, Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica, Reumatol Clin, 7, 113, 10.1016/j.reuma.2010.12.002 Den Broeder, 2002, Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF alpha, Rheumatology, 41, 638, 10.1093/rheumatology/41.6.638 Pavelka, 2009, Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, doble-blind study failed to confirm its efficacy, Ann Rheum Dis, 68, 1285, 10.1136/ard.2008.090860 Van den Bemt, 2008, Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study, Ann Rheum Dis, 67, 1697, 10.1136/ard.2007.083683 Smolen, 2013, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial, Lancet, 10.1016/S0140-6736(12)61811-X Berthelot, 2007, 25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy, Joint Bone Spine, 74, 144, 10.1016/j.jbspin.2006.03.010 Evaluation of a standardized protocol for dose reduction in patients with Spondylarthropathies and clinical remission with anti-TNF therapy. ClinicalTrials.gov Identifier: NCT01604629 Tak, 2011, Inhibition of joint damage and improved clinical outcome with rituximab plus methotrexate in early rheumatoid arthritis: The IMAGE trial, Ann Rheum Dis, 70, 39, 10.1136/ard.2010.137703 Chaztzidionysiou, 2012, Efficacy of different doses of rituximab for the treatment of RA: data from the CERERRA collaboration [EULAR 2012 Abstract OP0028], Ann Rheum Dis, 71, 110 Dougados, 2012, Ann Rheum Dis, 71, 121 Kobelt, 2011, Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment, Int J Technol Assess Health Care, 27, 193, 10.1017/S0266462311000195